Viromed Medical AG (ISIN: DE000A40ZVN7), a medical technology company specializing in cold plasma technology, announced that its multi-year research into the application of cold atmospheric plasma (CAP) in the lung has been successfully completed. The study data will now be submitted for publication in a renowned scientific journal.
The study focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine. Results confirm the potential of cold plasma as a physical, non-pharmacological treatment for severe infectious lung diseases. The data show a clearly defined therapeutic safety window and a complete reduction of pathogenic germs in lung epithelial models.
An important component was the ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School. The isolated, ventilation- and perfusion-capable lung model used realistically reflects key physiological characteristics of the human lung.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems. It is particularly encouraging that we are already seeing first successful applications in patients in a university clinical setting."
Based on the study results, Viromed's technology has already been used in a university setting in a severe pulmonary individual case in a human patient. Following approval by the responsible ethics committee, a university hospital with a department specializing in lung and transplantation medicine treated a patient in connection with a lung transplant and massive complications. The use of cold plasma was very successful, and according to the treating physicians, the observed positive clinical course was exceptional. The hospital plans to publish the case in the near term, and further severely ill patients are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by resistance development, cold plasma as a physical mode of action opens a new therapeutic dimension, also for prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis or application in the thorax for bacterial pleural empyema.
For more information, visit Viromed Medical AG.
